chemical

Tazemetostat EPZ-6438

HY-13803

10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg

76; 60; 84; 120; 190; 290 USD

Tazemetostat EPZ-6438

Chemical

10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg

76; 60; 84; 120; 190; 290 USD

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat (EPZ-6438) inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K i value of 2.5 nM. Tazemetostat (EPZ-6438) inhibits EZH2 with IC 50 s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat (EPZ-6438) inhibits rat EZH2 with an IC 50 of 4 nM. Tazemetostat (EPZ-6438) also inhibits EZH1 with an IC 50 of 392 nM [1] .

99.76%

Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.